Affiliations: [a] Rajko Medenica Research Foundation, San Diego, CA, USA | [b] Shantha West, Inc., San Diego, CA, USA | [c] University of California, San Diego; MAE Department | [d] Department of Pathology, Little Company of Mary Hospital, Torrance, CA, USA | [e] Pathology, Inc, Torrance, CA, USA | [f] Teikyo University, Department of Surgery, Tokyo, Japan | [g] National Medical Center, Department of Molecular and Cellular Biology, Budapest, Hungary
Correspondence:
[*]
Corresponding author: Mark C. Glassy, Ph.D., The Rajko Medenica Research Foundation, 10246 Parkdale Avenue, San Diego, CA 92126, USA. E-mail: markglassy@aol.com.
Abstract: A panel of four natural human monoclonal IgG antibodies derived from B lymphocytes isolated from regional draining lymph nodes of cancer patients has been developed and characterized. The four human antibodies are termed, RM1, RM2, RM3, and RM4. The immunoreactivity of this panel of four human antibodies is restricted to tumor cells. Individually, these human MAbs show tumor targeting and are effective in inhibiting tumor growth in nude mouse xenograft models. When used in combination the antibodies show an additive effect in slowing down the progression of tumors in xenograft models suggesting that cocktails of antibodies may be useful in the clinic.
